Introduction And Mechanism
- FibroScan utilizes vibration-controlled transient elastography to non-invasively assess liver fibrosis and steatosis.
- It functions as a rapid, 5 to 10-minute outpatient point-of-care procedure, replacing the need for invasive liver biopsies in pediatric chronic liver disease.
- Pediatric-specific S-probes are utilized for children under 3 years of age or those with smaller liver volumes.
| Parameter | Measurement Unit | Pathological Target | Clinical Significance |
|---|---|---|---|
| Liver Stiffness Measurement (LSM) | Kilopascals (kPa) | Hepatic Fibrosis | Correlates directly with METAVIR histological fibrosis stages (F0–F4). |
| Controlled Attenuation Parameter (CAP) | Decibels per meter (dB/m) | Hepatic Steatosis | Quantifies the degree of fat accumulation (S0–S3). |
Clinical Rationale And Pediatric Indications
- The pediatric burden of Metabolic Dysfunction-Associated Steatotic Liver Disease affects 20 to 30% of obese Indian children, mandating early fibrosis screening.
- Other primary indications include chronic viral hepatitis B and C, metabolic liver diseases, and post-Kasai monitoring in biliary atresia.
- Eliminates the inherent risks of traditional liver biopsy, including hemorrhage, required anesthesia, and localized sampling errors.
- FibroScan provides a highly cost-effective alternative (costing ₹1500–3000) compared to surgical biopsy, demonstrating a feasibility rate exceeding 95% in trained hands.
Diagnostic Interpretation And 2026 Evidence
- Accurate interpretation requires stringent quality control criteria, specifically an Interquartile Range to median ratio (IQR/median) strictly below 30%.
- Normal To Mild Fibrosis: LSM values strictly below 7 kPa generally indicate F0 to F1 stages.
- Significant Fibrosis: Multicenter 2026 Indian analyses confirm an LSM threshold of 8.2 kPa or higher accurately identifies significant fibrosis (F≥2) with a high negative predictive value.
- Advanced Fibrosis: Values exceeding 12 kPa strongly indicate advanced fibrosis, while in biliary atresia, an LSM >10 kPa post-Kasai predicts severe disease progression.
- FibroScan demonstrates superior diagnostic accuracy (AUROC 0.85–0.92) when compared to serum-based biomarkers like APRI or FIB-4 scores.
Current Society And Government Guidelines
International And National Consensus
- AASLD 2025 Guidelines: Strongly recommends FibroScan as the primary imaging tool for staging fibrosis, prioritizing it over isolated serum markers for MASLD and viral hepatitis.
- IAP 2025–2026 Recommendations: Endorses FibroScan as the first-line non-invasive screening tool for obese children presenting with elevated ALT levels prior to considering a biopsy.
- MoHFW/ICMR Integration: Officially incorporated into the 2025 Standard Treatment Workflows for Liver Failure and NAFLD.
- The procedure is increasingly covered under Ayushman Bharat PM-JAY at empaneled Centres of Excellence to support equitable access.
Implementation Challenges
- Absolute Contraindications: The procedure is strictly contraindicated in the presence of ascites.
- Technical Barriers: Narrow intercostal spaces in infants and severe central obesity can impair accurate probe placement and signal acquisition.
- Operational Challenges: High initial equipment costs restrict availability predominantly to urban tertiary care centers, necessitating highly trained operators for accurate pediatric interpretation.